Omalizumab appears to eliminate anaphylaxis risk and reduce reaction severity in alpha-gal syndrome patients, according to a study presented on Thursday at the American College of Allergy, Asthma and Immunology annual meeting.
For patients suffering from alpha-gal syndrome—a tick-triggered hypersensitivity to mammalian meat—avoidance has long been the only defense. New data presented this week challenge that paradigm, tracking patients who took the biologic medication omalizumab.
Omalizumab Prevents Anaphylaxis in Alpha-Gal Syndrome Patients
- What was studied: Researchers evaluated 64 alpha-gal syndrome patients treated with the biologic drug omalizumab (widely known as Xolair) for at least three months.
- The core finding: While 53% of the cohort had required emergency epinephrine prior to treatment, zero patients experienced anaphylaxis while actively taking the medication.
- Dietary impact: Roughly one-third of the study participants successfully reintroduced some mammalian products back into their daily diets.
Evaluating Efficacy in High-Risk Patients
As MedPage Today covered, the study’s principal investigator, University of North Carolina at Chapel Hill allergy and immunology fellow Collette M. Tilly, pointed out that the participants consisted of individuals facing severe clinical risks instead of milder cases.
Among the 64 patients evaluated between April 2022 and November 2025, 81% had documented baseline anaphylaxis reactions to alpha-gal, and 53% had previously required epinephrine. While on omalizumab, which had a median treatment duration of 23 months, none of those severe systemic events occurred.
Beyond zero instances of anaphylaxis, 95% of participants reported meaningful improvements in their overall reaction frequency or severity. Tilly said 33% of the cohort achieved at least partial reintroduction of mammalian products.
Candice Matthis of Charlottesville, Virginia, co-founder of the nonprofit Alpha-Gal Foundation who was not involved in the research, described the personal toll of managing unpredictable flares.
“I wasn't aware of alpha gal at the time,” Candice Matthis of Charlottesville, Virginia, co-founder of the nonprofit Alpha-Gal Foundation, told NBC News, noting she was diagnosed in 2019 after 12 years of symptoms and was prescribed omalizumab for other food allergies and subsequently noticed substantial protection against accidental exposures, such as mistakenly consuming whole milk in coffee.
Omalizumab Binds to IgE to Reduce Allergic Reactions
Omalizumab operates by binding to circulating immunoglobulin E (IgE), reducing the free antibodies available to trigger mast cells across various IgE-mediated triggers. Because its mechanism is not allergen-specific, the antibody is approved to treat food allergies broadly.
“[T]he rationale that specific-IgE is responsible for the reaction and that omalizumab reduces free, and ultimately mast cell bound, IgE provides a logical basis for benefit,” Dennis K. Ledford, MD, of the University of South Florida in Tampa, noted earlier this year.
However, experts emphasize that alpha-gal syndrome behaves differently than classical food allergies like peanuts. Jay Lieberman, MD, of the University of Tennessee Health Science Center in Memphis, pointed out that alpha-gal reactions rely heavily on co-factors such as fat content and portion size, making the condition less predictable.
Researchers also highlighted unanswered questions regarding natural disease progression. Pointing out that patient sensitivity can sometimes diminish naturally over time, Mount Sinai Health System allergy and systems biology professor Supinda Bunyavanich in New York City advocated for conducting a comprehensive prospective clinical trial. “It remains unclear whether omalizumab increased reaction thresholds, facilitated reintroduction in patients whose sensitivity was already waning, or both,” Tilly said.
Contraindications & When to Consult a Doctor
While adverse events were generally uncommon—mostly presenting as arthralgias—two patients in the study discontinued the biologic due to side effects. Investigators also said that omalizumab is manufactured in Chinese hamster ovary cells, which may variably glycosylate with alpha-gal, creating a theoretical risk of hypersensitivity in rare cases.
Future Directions and Prevention Protocols
While the study shows potential for reducing reaction severity, researchers emphasize that prospective, multicenter trials are required to establish standardized dosing regimens, optimal treatment durations, and exact discontinuation criteria.
In the interim, clinicians stress that pharmaceutical interventions do not replace foundational prevention. Mary McGintee, an allergist not involved with the study, advised patients to maintain rigorous tick-avoidance measures when spending time outdoors in wooded or grassy areas where deer and small rodents reside, utilizing appropriate repellents on both skin and clothing.
References
- MedPage Today: Omalizumab Linked With Anaphylaxis Elimination in Meat Allergy
- NBC News: For alpha-gal patients, allergy drug could cut the severity of reactions to red meat
- Newser: A Common Drug May Help With New Red-Meat Allergy
- Centers for Disease Control and Prevention: Morbidity and Mortality Weekly Report
Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Earlier coverage: Omalizumab Shows Promise in Reducing Anaphylaxis for Alpha-Gal Syndrome Patients
